Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

REPL

+ Watchlist+ Portfolio

Replimune Group, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$19.69
52-Week Range
$1.50 – $23.54
Market Cap
$1.88B
P/E (TTM)
—
EPS (TTM)
-2.79
Dividend Yield
0.00%
Advanced Metrics
Price/Book
9.17
PEG Ratio
—
Return on Equity
-115.80%
Return on Assets
-43.95%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
7.11
Debt/Equity
0.62
Total Debt
$127.19M
Free Cash Flow
$-148.30M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.70B

Market Snapshot

About

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment. The company focuses on engineered oncolytic viruses that selectively replicate in tumors to kill cancer cells while stimulating anti-tumor immune responses. Its lead candidate targets multiple solid tumor types.